2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID 1) study was a phase 1/phase 2 first-in-human clinical gene therapy trial using an adeno-associated virus serotype 1 (AAV1) vector carrying the sarcoplasmic reticulum calcium ATPase gene (AAV1/SERCA2a) in patients with advanced heart failure. The study explored potential benefits of the therapy at 12 months, and results were previously reported.

          Related collections

          Author and article information

          Journal
          Circ. Res.
          Circulation research
          1524-4571
          0009-7330
          Jan 3 2014
          : 114
          : 1
          Affiliations
          [1 ] From the Celladon Corporation, San Diego, CA (K.Z., J.J.R., K.W.); AY Statistical Consulting, San Andreas, CA (A.Y.); The University of California, San Diego Medical Center, La Jolla (B.G.); Penn Heart and Vascular Center, Hospital of the University of Pennsylvania, Philadelphia (M.J.); and Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY (R.J.H.).
          Article
          CIRCRESAHA.113.302421
          10.1161/CIRCRESAHA.113.302421
          24065463
          c6319fdc-c294-4b90-9fbb-4def75ac5cde
          History

          clinical trial,genetic therapy,heart failure,sarcoplasmic reticulum calcium-transporting ATPases

          Comments

          Comment on this article